Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Wisconsin for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Wisconsin only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Wisconsin (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kurt Oelke (NPI 1962433136)

Field	Value
Entity Type	Individual
Organization	Kurt Oelke
Address	7080 N Port Washington Rd
City	Glendale
State	WI
ZIP	53217
Taxonomy	Rheumatology Physician
NPI Enumerated	July 6, 2006

Payer Source	Total Paid
Medicare	$794.2K
Medicaid	$0

Key Findings

This provider’s commercial billing footprint is effectively single-payer: lifetime Medicare revenue totals $794.2K while Medicaid billing is listed as none, so Medicare is the sole recorded public payer on file. That concentration means analyses of utilization and revenue trends will be driven entirely by Medicare activity rather than a mixed Medicare/Medicaid mix.

Revenue is highly concentrated in biologic infusion J‑codes: J0129, J9312, and J1745 together account for 83.5% of the provider’s Medicare revenue, signaling the practice is primarily generating income from high-cost infused or injected biologic therapies. The presence of these specific J‑codes (abatacept J0129, rituximab J9312, infliximab J1745) aligns with rheumatology specialty care that administers office‑based biologic infusions.

Detail on the top drivers shows a heavy single-code dependency: J0129 comprises $409.7K (51.5% of Medicare revenue), followed by J9312 at $161.3K (20.3%) and J1745 at $93.3K (11.7%). Given those figures, more than half of Medicare dollars come from one drug code (J0129), which concentrates reimbursement risk and operational focus on abatacept administration.

Operationally, the billing mix indicates on‑site infusion capability beyond drug reimbursement: chemotherapy/infusion administration codes such as 96413, 96365 and the add‑on 96415 appear on the profile (96413: $16.3K; 96365: $9.1K; 96415: $3K), supporting that staff and workflow accommodate IV infusions and multi‑hour administration sessions. These administration codes are smaller contributors by revenue but confirm the practice delivers parenteral therapies rather than only office visits.

Clinical visit coding is a minor portion of Medicare receipts: 99214 accounts for $26.4K (3.3%) and 99213 $7.7K (1.0%), which indicates the practice’s top-line is dominated by drug and infusion reimbursement rather than evaluation & management visits. This suggests business operations are centered on infusion throughput and drug procurement/administration rather than high-volume office E/M revenue.

Compared with national peers, the provider is a modest participant for its highest‑revenue drugs: J0129 ranks #367 of 1221 (70th percentile, described as typical, unremarkable volume), J9312 ranks #197 of 317 (38th percentile), and J1745 ranks #562 of 1352 (58th percentile). Those rank/percentile positions indicate solid activity for J0129 but no indication of being a dominant national outlier; overall competitive standing is consistent with a mid‑level regional infusion provider rather than a top national center.

While many procedure and drug codes are characterized in the file as "typical, unremarkable volume for this code," several routine lab and injection services show relatively high peer percentiles—examples include 82565 at rank #413 of 5066 (92th percentile) and 96372 at rank #6407 of 58224 (89th percentile). This pattern suggests stronger‑than‑average throughput for monitoring and injection support services that accompany an infusion‑centric rheumatology practice.

The provider’s NPI tenure (NPI enumerated 2006-07-06 (~20 years ago)) indicates an established practice presence; combined with the concentrated Medicare revenue profile, this longevity supports an operational model refined around biologic infusion delivery. Dependence on Medicare and on a small set of high‑revenue J‑codes should be considered when projecting future revenue sensitivity to payer policy or drug utilization shifts.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

37 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	12,050	$30	$409.7K
J9312	Injection, rituximab, 10 mg	2,560	$60	$161.3K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,590	$30	$93.3K
J0897	Injection, denosumab, 1 mg	2,460	$20	$44.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	310	$90	$26.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	170	$90	$16.3K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	190	$50	$9.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	130	$60	$7.7K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	40	$120	$4.3K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	380	$10	$3K

Showing 1–10 of 37

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 37 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Wisconsin Distribution

Kurt Oelke — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Wisconsin

Full comparison — all codes billed, vs. state median

37 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	4	10	8,170	$30	$286.2K
J9312	5	10	2,580	$60	$234.8K
J1745	11	20	6,060	$30	$168.9K
J0897	24	60	2,220	$20	$69.3K
96413	20	80	110	$90	$12.7K
86480	8	10	20	$60	$12.2K
99214	849	9,800	80	$70	$9.2K
96365	18	90	50	$50	$5.8K
99213	1,766	9,380	60	$50	$4.7K
86803	12	10	40	$10	$4.1K

Showing 1–10 of 37

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kurt Oelke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rheumatic Disease Center	WI	Rheumatology Physician	$0	$3M
John Albert	WI	Rheumatology Physician	$1.2M	$0
Farrukh Pasha	WI	Rheumatology Physician	$314.9K	$0
Suhail Hameed	WI	Rheumatology Physician	$302.5K	$0
Steven Bergquist	WI	Rheumatology Physician	$90.3K	$0
Jonathan Kushi	WI	Rheumatology Physician	$66.8K	$0
Katherine Finn	WI	Rheumatology Physician	$31.5K	$0
Juliana Shah	WI	Adult Health Nurse Practitioner	$15.5K	$0

Nearby Providers

Other providers in the same ZIP code as Kurt Oelke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
St. Francis Children's Center	WI	Rehabilitation Clinic/Center	$0	$6.1M
Great Lakes Hospice LLC	WI	Community Based Hospice Care Agency	$0	$1.9M
Rahul Sawlani	WI	Diagnostic Radiology Physician	$329.3K	$29.7K
Melissa High	WI	Physical Therapist	$115.4K	$0
Sharon Schulman	WI	Psychologist	$84.8K	$0
Cathy Perkins	WI	Psychosomatic Medicine Physician	$82.4K	$0
James Berman	WI	Dermatology Physician	$77.8K	$0
Paul Smerz	WI	Clinical Psychologist	$45.6K	$0
David Schulz	WI	Psychiatry Physician	$16.9K	$0
Christina Petrou	WI	Optometrist	$12.7K	$0

Kurt Oelke — Billing Profile & Reimbursement Data

Sign up for Kurt Oelke — Billing Profile & Reimbursement Data policy alerts

Kurt Oelke — Billing Profile & Reimbursement Data

Sign up for Kurt Oelke — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References